Merck KGaA (XETRA:MRK) — Market Cap & Net Worth
Market Cap & Net Worth: Merck KGaA (MRK)
Merck KGaA (XETRA:MRK) has a market capitalization of $19.78 Billion (€16.92 Billion) as of September 16, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #1296 globally and #289 in its home market, demonstrating a -3.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Merck KGaA's stock price €130.90 by its total outstanding shares 129242251 (129.24 Million). Also see total assets of Merck KGaA for a full breakdown of the balance sheet.
Merck KGaA Market Cap History: 2015 to 2026
Merck KGaA's market capitalization history from 2015 to 2026. Data shows growth from $11.93 Billion to $19.78 Billion (5.90% CAGR). Also see how efficiently does Merck KGaA generate cash for how efficiently the company converts equity into cash flow.
Index Memberships
Merck KGaA is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
HDAX Performance
GDAXHI
|
$1.39 Trillion | 1.43% | #17 of 99 |
|
HDAX Price
GDAXHIP
|
$1.40 Trillion | 1.41% | #17 of 102 |
|
DAX Index
GDAXI
|
$1.19 Trillion | 1.66% | #16 of 40 |
|
DAX Price
GDAXIP
|
$1.19 Trillion | 1.66% | #16 of 40 |
|
STOXX Europe Large 200 EUR Price
LCXP
|
$7.27 Trillion | 0.27% | #84 of 182 |
|
STOXX Europe Large 200 Net Return
LCXR
|
$7.27 Trillion | 0.27% | #84 of 182 |
Weight: Merck KGaA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Merck KGaA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Merck KGaA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check MRK share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.88x
Merck KGaA's market cap is 0.88 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.10x
Merck KGaA's market cap is 7.10 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $13.38 Billion | $15.02 Billion | $1.63 Billion | 0.89x | 8.21x |
| 2017 | $12.24 Billion | $14.52 Billion | $2.60 Billion | 0.84x | 4.70x |
| 2018 | $12.46 Billion | $14.84 Billion | $1.13 Billion | 0.84x | 11.03x |
| 2019 | $14.79 Billion | $16.15 Billion | $1.32 Billion | 0.92x | 11.20x |
| 2020 | $20.20 Billion | $17.53 Billion | $1.99 Billion | 1.15x | 10.16x |
| 2021 | $32.99 Billion | $19.69 Billion | $3.06 Billion | 1.68x | 10.80x |
| 2022 | $26.57 Billion | $22.23 Billion | $3.33 Billion | 1.19x | 7.99x |
| 2023 | $21.46 Billion | $20.99 Billion | $2.82 Billion | 1.02x | 7.60x |
| 2024 | $21.14 Billion | $21.16 Billion | $2.78 Billion | 1.00x | 7.61x |
| 2025 | $18.52 Billion | $21.10 Billion | $2.61 Billion | 0.88x | 7.10x |
Competitor Companies of MRK by Market Capitalization
Companies near Merck KGaA in the global market cap rankings as of September 16, 2026. Review tangible equity quality of Merck KGaA to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Merck KGaA by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Merck KGaA Historical Marketcap From 2015 to 2026
Between 2015 and today, Merck KGaA's market cap moved from $11.93 Billion to $ 19.78 Billion, with a yearly change of 5.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €19.78 Billion | +6.77% |
| 2025 | €18.52 Billion | -12.37% |
| 2024 | €21.14 Billion | -1.49% |
| 2023 | €21.46 Billion | -19.23% |
| 2022 | €26.57 Billion | -19.46% |
| 2021 | €32.99 Billion | +63.33% |
| 2020 | €20.20 Billion | +36.58% |
| 2019 | €14.79 Billion | +18.63% |
| 2018 | €12.46 Billion | +1.79% |
| 2017 | €12.24 Billion | -8.46% |
| 2016 | €13.38 Billion | +12.13% |
| 2015 | €11.93 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Merck KGaA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $19.78 Billion USD |
| MoneyControl | $19.78 Billion USD |
| MarketWatch | $19.78 Billion USD |
| marketcap.company | $19.78 Billion USD |
| Reuters | $19.78 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Merck KGaA
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for re… Read more